The Brigham and Women's Hospital, Inc.

Invictus Oncology Pvt. Ltd.

Strategic Capital Network, LLC

Ashish Kulkarni

Shiladitya Sengupta

Bhaskar Roy

Poornima Rao

Monideepa Roy

Soulaymane Kachani

Anubhab Mukherjee

Brian A Hunter

Aaron Goldman

Goutam Biswas

Hemant Suryavanshi

Described herein is a reporter material platform that can be used to directly monitor the drug response in real-time. The reporter material can include an activator element which undergoes a chemical change in response to an immunonological response to a drug, and the chemical change can be detected using a reporter element. The reporter material can include a drug and a reporter element that are physically constrained in a close proximity. The reporter element produces a signal only when the drug induces a direct or indirect physiological change in the tumor or surrounding tissue. The reporter material platform can self-assemble via supramolecular interactions. This reporter material platform can be used to directly monitor the drug response in real-time.

Reporter platform for real time monitoring of drug efficacy

The compositions and methods described herein relate to the treatment of cancer, e.g. by reducing the regression of cancer cells from regressing into cancer stem cell-like phenotypes and/or reducing the development of drug-resistant cancer cells. In some embodiments, the compositions and methods relate to inhibitors of PI3K pathway kinases and Src family kinases.

Methods and compositions relating to the treatment of cancer

The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula I, compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/CSF1R signalling pathway with decreased toxicity. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a CSF-1R inhibitor is combined with one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid. The present disclosure also provides a method for treating cancer, allergy, Systemic lupus erythematosus, nephritis, Chronic Obstructive Pulmonary Disease, and abnormal macrophage functions or any combinations thereof. 

Cellular signalling inhibitors, their formulations and methods thereof

Described herein are compositions and methods relating to chemotherapeutic agent conjugates and the treatment of cancer.

Compositions for treating cancer and methods for making the same

An improved resource allocation system comprising a reliability decision engine (), which allocates the portfolio's assets as required for the desired reliability portfolio. The reliability decision engine including two reliability decision engines, a basic reliability decision engine () and a robust reliability decision engine (). The use of robust optimization makes it possible to determine the sensitivity of the optimized portfolio. Scenarios can be specified directly by the user or automatically generated by the system in response to a selection by the user. Inputs () are applied to basic the basic reliability decision engine () and inputs () are applied to robust reliability decision engine ().

Growing community of inventors

Waltham, MA, United States of America

Ashish Kulkarni